Skip to main content
Top
Published in: Infectious Diseases and Therapy 2/2016

Open Access 01-06-2016 | Case Report

Acute Angioedema Triggered by Daptomycin

Authors: Valentin Gisler, Sabine Müller, Lionel Müller, Lukas Jörg-Walther, Parham Sendi

Published in: Infectious Diseases and Therapy | Issue 2/2016

Login to get access

Abstract

Introduction

Daptomycin is a cyclic lipopeptide antibiotic, frequently administered for Staphylococcus aureus bloodstream infections. Numerous studies have shown that daptomycin is relatively safe and well tolerated. Serious adverse events possibly related to this antimicrobial compound are rare. We report a case of acute angioedema triggered by daptomycin.

Case Report

A 60-year-old woman with S. aureus bacteremia without identified source was treated intravenously with high-dose beta-lactams at our institution. Because S. aureus bacteremia persisted on day 6, and in parallel, acute kidney injury developed, antimicrobial treatment was switched to a combination therapy with daptomycin and ceftriaxone. Shortly after completion of the first daptomycin administration, the patient developed lip and tongue swelling and dyspnea. Acute angioedema was clinically evident. Antibiotic therapy was switched to vancomycin, and the further clinical course was favorable. An intradermal test showed a significant wheal diameter for daptomycin, but negative results for ceftriaxone.

Conclusion

The association with daptomycin in this case is either probable or certain. Clinicians should be aware that daptomycin can cause immediate-type hypersensitivity reactions, including acute angioedema, even upon first administration.
Literature
3.
go back to reference Seaton RA, Menichetti F, Dalekos G, Beiras-Fernandez A, Nacinovich F, Pathan R, Hamed K. Evaluation of effectiveness and safety of high-dose daptomycin: results from patients included in the European Cubicin® outcomes registry and experience. Adv Ther. 2015;32(12):1192–205.CrossRefPubMedPubMedCentral Seaton RA, Menichetti F, Dalekos G, Beiras-Fernandez A, Nacinovich F, Pathan R, Hamed K. Evaluation of effectiveness and safety of high-dose daptomycin: results from patients included in the European Cubicin® outcomes registry and experience. Adv Ther. 2015;32(12):1192–205.CrossRefPubMedPubMedCentral
4.
go back to reference Mehta S, Singh C, Plata KB, Chanda PK, Paul A, Riosa S, Rosato RR, Rosato AE. beta-Lactams increase the antibacterial activity of daptomycin against clinical methicillin-resistant Staphylococcus aureus strains and prevent selection of daptomycin-resistant derivatives. Antimicrob Agents Chemother. 2012;56(12):6192–200.CrossRefPubMedPubMedCentral Mehta S, Singh C, Plata KB, Chanda PK, Paul A, Riosa S, Rosato RR, Rosato AE. beta-Lactams increase the antibacterial activity of daptomycin against clinical methicillin-resistant Staphylococcus aureus strains and prevent selection of daptomycin-resistant derivatives. Antimicrob Agents Chemother. 2012;56(12):6192–200.CrossRefPubMedPubMedCentral
6.
go back to reference Bagwell AD, Stollings JL, White KD, Fadugba OO, Choi JJ. Linezolid desensitization for a patient with multiple medication hypersensitivity reactions. Ann Pharmacother. 2013;47(7–8):e30.CrossRefPubMed Bagwell AD, Stollings JL, White KD, Fadugba OO, Choi JJ. Linezolid desensitization for a patient with multiple medication hypersensitivity reactions. Ann Pharmacother. 2013;47(7–8):e30.CrossRefPubMed
7.
go back to reference Metz GM, Thyagarajan A. A successful protocol for daptomycin desensitization. Ann Allergy Asthma Immunol. 2008;100(1):87.CrossRefPubMed Metz GM, Thyagarajan A. A successful protocol for daptomycin desensitization. Ann Allergy Asthma Immunol. 2008;100(1):87.CrossRefPubMed
8.
go back to reference Jones JM, Richter LM, Alonto A, Leedahl DD. Desensitization to ceftaroline in a patient with multiple medication hypersensitivity reactions. Am J Health Syst Pharm. 2015;72(3):198–202.CrossRefPubMed Jones JM, Richter LM, Alonto A, Leedahl DD. Desensitization to ceftaroline in a patient with multiple medication hypersensitivity reactions. Am J Health Syst Pharm. 2015;72(3):198–202.CrossRefPubMed
9.
go back to reference Fowler VG Jr, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, Levine DP, Chambers HF, Tally FP, Vigliani GA, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006;355(7):653–65.CrossRefPubMed Fowler VG Jr, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, Levine DP, Chambers HF, Tally FP, Vigliani GA, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006;355(7):653–65.CrossRefPubMed
10.
go back to reference Gonzalez-Ruiz A, Gargalianos-Kakolyris P, Timerman A, Sarma J, Ramallo VJG, Bouylout K, Trostmann U, Pathan R, Hamed K. Daptomycin in the clinical setting: 8-year experience with Gram-positive bacterial infections from the EU-CORE(SM) registry. Adv Ther. 2015;32(6):496–509.CrossRefPubMedPubMedCentral Gonzalez-Ruiz A, Gargalianos-Kakolyris P, Timerman A, Sarma J, Ramallo VJG, Bouylout K, Trostmann U, Pathan R, Hamed K. Daptomycin in the clinical setting: 8-year experience with Gram-positive bacterial infections from the EU-CORE(SM) registry. Adv Ther. 2015;32(6):496–509.CrossRefPubMedPubMedCentral
11.
go back to reference Guleri A, Utili R, Dohmen P, Petrosillo N, Piper C, Pathan R, Hamed K. Daptomycin for the treatment of infective endocarditis: results from European Cubicin® outcomes registry and experience (EU-CORE). Infect Dis Ther. 2015;4(3):283–96.CrossRefPubMedPubMedCentral Guleri A, Utili R, Dohmen P, Petrosillo N, Piper C, Pathan R, Hamed K. Daptomycin for the treatment of infective endocarditis: results from European Cubicin® outcomes registry and experience (EU-CORE). Infect Dis Ther. 2015;4(3):283–96.CrossRefPubMedPubMedCentral
12.
go back to reference Keil F, Daikos GL, Skoutelis A, Dominguez JI, Pathan R, Hamed K. Daptomycin for Gram-positive infections in patients with neutropenia: clinical experience from a European outcomes registry. Adv Ther. 2015;32(8):715–26.CrossRefPubMedPubMedCentral Keil F, Daikos GL, Skoutelis A, Dominguez JI, Pathan R, Hamed K. Daptomycin for Gram-positive infections in patients with neutropenia: clinical experience from a European outcomes registry. Adv Ther. 2015;32(8):715–26.CrossRefPubMedPubMedCentral
13.
go back to reference Seaton RA, Gonzalez-Ruiz A, Cleveland KO, Couch KA, Pathan R, Hamed K. Real-world daptomycin use across wide geographical regions: results from a pooled analysis of CORE and EU-CORE. Ann Clin Microbiol Antimicrob. 2016;15(1):18.CrossRefPubMedPubMedCentral Seaton RA, Gonzalez-Ruiz A, Cleveland KO, Couch KA, Pathan R, Hamed K. Real-world daptomycin use across wide geographical regions: results from a pooled analysis of CORE and EU-CORE. Ann Clin Microbiol Antimicrob. 2016;15(1):18.CrossRefPubMedPubMedCentral
14.
go back to reference Hagiya H, Kimura M, Miyamoto T, Haruki Y, Otsuka F. Acute generalized exanthematous pustulosis caused by daptomycin in a critically ill burn victim. Intern Med. 2014;53(5):511–4.CrossRefPubMed Hagiya H, Kimura M, Miyamoto T, Haruki Y, Otsuka F. Acute generalized exanthematous pustulosis caused by daptomycin in a critically ill burn victim. Intern Med. 2014;53(5):511–4.CrossRefPubMed
16.
go back to reference Antunez C, Martin E, Cornejo-Garcia JA, Blanca-Lopez N, Mayorga C, Torres MJ, Blanca M. Immediate hypersensitivity reactions to penicillins and other betalactams. Curr Pharm Des. 2006;12(26):3327–33.CrossRefPubMed Antunez C, Martin E, Cornejo-Garcia JA, Blanca-Lopez N, Mayorga C, Torres MJ, Blanca M. Immediate hypersensitivity reactions to penicillins and other betalactams. Curr Pharm Des. 2006;12(26):3327–33.CrossRefPubMed
17.
go back to reference Barbaud A, Goncalo M, Bruynzeel D, Bircher A, European Society of Contact D. Guidelines for performing skin tests with drugs in the investigation of cutaneous adverse drug reactions. Contact Dermat. 2001;45(6):321–8.CrossRef Barbaud A, Goncalo M, Bruynzeel D, Bircher A, European Society of Contact D. Guidelines for performing skin tests with drugs in the investigation of cutaneous adverse drug reactions. Contact Dermat. 2001;45(6):321–8.CrossRef
Metadata
Title
Acute Angioedema Triggered by Daptomycin
Authors
Valentin Gisler
Sabine Müller
Lionel Müller
Lukas Jörg-Walther
Parham Sendi
Publication date
01-06-2016
Publisher
Springer Healthcare
Published in
Infectious Diseases and Therapy / Issue 2/2016
Print ISSN: 2193-8229
Electronic ISSN: 2193-6382
DOI
https://doi.org/10.1007/s40121-016-0111-4

Other articles of this Issue 2/2016

Infectious Diseases and Therapy 2/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.